Value20202021202220232024TTMSelling/general/admin expenses67.1 M63.22 M62.68 M61.17 M44.73 M36.99 MResearch & development180.65 M230.82 M249.9 M234.06 M111.52 M104.91 MOperating income129.55 M183.34 M201.28 M274 M103.97 M87.76 MNon-Operating Income, Total0—————Interest expense, net of interest capitalized——————Non-Operating Income, excl. Interest Expenses0—————Unusual income/expense——————Pretax income120.78 M177.99 M191.85 M262.9 M98.11 M87.83 MEquity in earnings——————Taxes345 K306 K429 K5.07 M167 K214 KNon-controlling/minority interest126 K11 K00——After tax other income/expense———1.12 M330 K361 KNet income before discontinued operations121 M178.29 M192.3 M257.83 M97.94 M87.56 MDiscontinued operations——————Net income121 M178.29 M192.3 M257.83 M97.94 M87.56 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders121 M178.29 M192.3 M257.83 M97.94 M87.56 MBasic earnings per share (Basic EPS)—-1.23-1.25-1.48-0.49-0.42Diluted earnings per share (Diluted EPS)—-1.23-1.25-1.48-0.49-0.4Average basic shares outstanding—144.57 M154.34 M174.44 M201.7 M983.3 MDiluted shares outstanding—144.57 M154.34 M174.44 M201.7 M983.3 MEBITDA——————EBIT——————Cost of revenue——————Other cost of goods sold——————Depreciation & amortization (cash flow)5.7 M9.4 M12.1 M15.1 M5.1 M4.24 M
Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc. is an American biotechnology company based in Brisbane, California, that develops cell and gene therapies for severe genetic diseases.